PURPOSE OF REVIEW: Widespread use of antiretroviral therapy (ART) has led to near-normal life expectancy in people with human immunodeficiency virus (HIV) infection. However, neurologic complications of HIV remain common; can affect any part of the neuraxis; and are due to direct effects of the virus, immunosuppression because of untreated HIV infection, aberrant immune responses in the setting of ART initiation, and ART toxicities. RECENT FINDINGS: HIV-associated neurocognitive disorder (HAND) remains one of the most common neurologic complications of HIV encountered today, but milder forms predominate in people on ART. No specific treatments for HAND exist, but small trials and epidemiologic evidence suggest paroxetine, intranasal insulin, and maraviroc may have utility in its treatment; further trials of these agents are ongoing. Widespread ART use has decreased the incidence of central nervous system opportunistic infections, but prognosis often remains poor in those who develop opportunistic infections. High-titer positive serum cryptococcal antigen is strongly predictive of cryptococcal meningitis and provides a tool to enhance diagnosis in areas with limited resources. HIV is an independent risk factor for stroke, and accelerated aging associated with HIV infection results in neurologic diseases of older age occurring at much younger ages in individuals infected with HIV. Ongoing HIV replication in the CSF despite peripheral virologic suppression may contribute to the development of HAND and may not improve despite adjusting the ART regimen to increase central nervous system penetrance. SUMMARY: Neurologists are likely to encounter patients infected with HIV in clinical practice. This article reviews the presentation, diagnosis, and management of the most common neurologic conditions associated with HIV infection and ART.
PURPOSE OF REVIEW: Widespread use of antiretroviral therapy (ART) has led to near-normal life expectancy in people with human immunodeficiency virus (HIV) infection. However, neurologic complications of HIV remain common; can affect any part of the neuraxis; and are due to direct effects of the virus, immunosuppression because of untreated HIV infection, aberrant immune responses in the setting of ART initiation, and ART toxicities. RECENT FINDINGS:HIV-associated neurocognitive disorder (HAND) remains one of the most common neurologic complications of HIV encountered today, but milder forms predominate in people on ART. No specific treatments for HAND exist, but small trials and epidemiologic evidence suggest paroxetine, intranasal insulin, and maraviroc may have utility in its treatment; further trials of these agents are ongoing. Widespread ART use has decreased the incidence of central nervous system opportunistic infections, but prognosis often remains poor in those who develop opportunistic infections. High-titer positive serum cryptococcal antigen is strongly predictive of cryptococcal meningitis and provides a tool to enhance diagnosis in areas with limited resources. HIV is an independent risk factor for stroke, and accelerated aging associated with HIV infection results in neurologic diseases of older age occurring at much younger ages in individuals infected with HIV. Ongoing HIV replication in the CSF despite peripheral virologic suppression may contribute to the development of HAND and may not improve despite adjusting the ART regimen to increase central nervous system penetrance. SUMMARY: Neurologists are likely to encounter patientsinfected with HIV in clinical practice. This article reviews the presentation, diagnosis, and management of the most common neurologic conditions associated with HIV infection and ART.
Authors: Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath Journal: Neurology Date: 2013-04-09 Impact factor: 9.910
Authors: Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: J A McCutchan; J A Marquie-Beck; C A Fitzsimons; S L Letendre; R J Ellis; R K Heaton; T Wolfson; D Rosario; T J Alexander; C Marra; B M Ances; I Grant Journal: Neurology Date: 2012-02-14 Impact factor: 9.910
Authors: David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant Journal: J Neurovirol Date: 2010-12-21 Impact factor: 2.643
Authors: Kate M Crossley; Shruti Agnihotri; Joga Chaganti; Michael L Rodriguez; Leon Patrick McNally; Nagagopal Venna; Sarah E Turbett; Matthew Gutman; Adrienne Morey; Igor J Koralnik; Bruce J Brew Journal: J Neurovirol Date: 2016-01-04 Impact factor: 2.643
Authors: Alyssa C Vecchio; Christina M Marra; Jeffrey Schouten; Hongyu Jiang; Johnstone Kumwenda; Khuanchai Supparatpinyo; James Hakim; Ned Sacktor; Thomas B Campbell; Srikanth Tripathy; Nagalingeswaran Kumarasamy; Alberto La Rosa; Breno Santos; Marcus T Silva; Cecilia Kanyama; Cindy Firnhaber; Mina C Hosseinipour; Rosie Mngqibisa; Colin Hall; Paola Cinque; Kevin Robertson Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: Ana C Villegas; Deanna Saylor; Michelle Kvalsund; Masharip Atadzhanov; Clarence Chiluba; Lorraine Chishimba; Stanley Zimba; Mashina Chomba; Omar K Siddiqi Journal: Hum Resour Health Date: 2021-07-16